Free Trial
→ Stunning new initiative unfolding in the White House? (From Paradigm Press) (Ad)tc pixel
Liisa Bayko

Liisa Bayko Analyst Performance

Managing Director at Evercore ISI

Liisa Bayko is a stock analyst at Evercore ISI focused in the medical sector, covering 21 publicly traded companies. Over the past year, Liisa Bayko has issued 7 stock ratings, including buy and hold recommendations. While full access to Liisa Bayko's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Liisa Bayko's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
41 Last 11 Years
Buy Recommendations
85.37% 35 Buy Ratings
Companies Covered
21 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy85.4%35 ratings
Hold9.8%4 ratings
Sell4.9%2 ratings

Out of 41 total stock ratings issued by Liisa Bayko at Evercore ISI, the majority (85.4%) have been Buy recommendations, followed by 9.8% Hold and 4.9% Sell.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
21 companies

Liisa Bayko, an analyst at Evercore ISI, currently covers 21 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
20 companies		95.2%
Miscellaneous
1 company		4.8%

Liisa Bayko of Evercore ISI specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
9 companies		42.9%
MED - DRUGS
5 companies		23.8%
PHARMACEUTICAL PREPARATIONS
5 companies		23.8%
BIOTECHNOLOGY
1 company		4.8%
Miscellaneous
1 company		4.8%

Liisa Bayko's Ratings History at Evercore ISI

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export to Excel
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
9/15/2025Lower Price Target$7.84$12.00Outperform
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
9/11/2025Lower Price Target$390.80$475.00Outperform
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
9/11/2025Boost Price Target$468.51$515.05Outperform
Savara Inc. stock logo
SVRA
Savara
5/28/2025Lower Price Target$2.09$2.00In-Line
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2/14/2025Upgrade$43.49$99.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2/12/2025Boost Price Target$24.01$45.00Outperform
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
1/13/2025Boost Price Target$7.63$12.00Outperform
Today's Ratings
Top-Rated Stocks
More Ratings Tools